Opioids for the management of breakthrough pain in cancer patients

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Zeppetella, Giovambattista ^a   Davies, Andrew N ^b  

^a St Clare Hospice   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; BREAKTHROUGH PAIN; COMPLICATION; HUMAN; INTRANASAL DRUG ADMINISTRATION; META ANALYSIS; NEOPLASM; ORAL DRUG ADMINISTRATION; PAIN MEASUREMENT; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

FENTANYL; MORPHINE; NARCOTIC ANALGESIC AGENT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; FENTANYL; HUMANS; MORPHINE; NEOPLASMS; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84961004726     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004311.pub4     Document Type: Review

References (64)

1. Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. Journal of Clinical Oncology 1998;16(10):3238-45.
2. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Douleurs 2002;3(1):26-35.
3. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91(1-2):123-30.
4. Fallon M, Reale C, Davies A, Lux AE, Kumar K, Stachowiak A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. Journal of Supportive Oncology 2011;9(6):224-31.
5. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. Journal of the National Cancer Institute 1998;90(8):611-6.
6. Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clinical Therapeutics 2009;31(6):1177-91.
7. Lennernäs B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliative Medicine 2010;24(3):286-93.
8. Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. British Journal of Cancer 2007;96(12):1828-33.
9. Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Current Medical Research and Opinion 2009;25(11):2805-15.
10. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79(2-3):303-12.
11. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clinical Journal of Pain 2006;22(9):805-11.
12. Portenoy RK, Burton AW, Gabrail N, Taylor D. Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010;151(3):617-24.
13. Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Current Medical Research and Opinion 2009;25(12):2877-85.
14. Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Annals of Oncology 2010;21(6):1308-14.
15. Rauch R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Current Medical Research and Opinion 2012;28(5):859-70.
16. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. Journal of Supportive Oncology 2007;5(7):327-34.
17. Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anaesthesia and Analgesia 2011;112(3):693-702.
18. Cleary JF. Double blind, randomized study of the treatment of breakthrough pain in cancer patients: oral transmucosal fentanyl citrate versus placebo. Proceedings of the American Society of Clinical Oncology 1997;16:52a.
19. Coluzzi P. A titration study of oral transmucosal fentanyl citrate for breakthrough pain in cancer patients. Proceedings of the American Society of Clinical Oncology 1997;16:52a.
20. Coluzzi PH, Schwartzberg L, Conroy Jr. JD, Charapata S, Gay M, Busch MA, et al. A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) [Les acces douloureux paroxystiques chez les patients cancereux: essai randomise comparant le citrate de fentanyl par voie orale transmuqueuse (OTFC) et le sulfate de morphine a liberation immediate (MLI)]. Douleurs 2002;3(1):26-35.
21. Davies A, Sitte T, Elsner F, Reale C, Espinosa J, Brooks D, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. Journal of Pain and Symptom Management 2011;41(2):358-66.
22. Hagen NA, Moulin DE, Brasher PM, Biondo PD, Eliasziw M, Watanabe SM, et al. A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliative Medicine 2010;24(7):696-706.
23. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management 2010;39(2):167-79.
24. Pasqualucci V, Tantucci C, Paoletti F, Dottorini ML, Bifarini G, Belfiore R, et al. Buprenorphine vs. morphine via the epidural route: a controlled clinical study of respiratory effects and analgesic activity. Pain 1987;29(3):273-86.
25. Rauck R, Stearns L, Scherlis M, Parikh N, Dillaha L. Fentanyl sublingual (SL) spray: reduction of breakthrough cancer pain 5-minutes post dose. Journal of Pain 2011;4 (Suppl):P50.
26. Rauck R, Stearns L, Scherlis M, Parikh N, Dillaha L. Reduction of breakthrough cancer pain at 5 minutes post dose. Pain Practice 2012;12:192-3.
27. Reynolds L, Geach J, Parikh N, Dillaha L, Bull J. Safety and efficacy of fentanyl sublingual (SL) spray in the treatment of breakthrough cancer pain. Journal of Pain 2011;12(4 Suppl):P50.
28. Reynolds L, Geach J, Parikh N, Dillaha L, Bull J. Safety and efficacy of fentanyl sublingual (SL) spray in the treatment of breakthrough cancer pain. Pain Practice 2012;12:193.
29. Shaiova L, Lapin J, Manco LS, Shasha D, Hu K, Harrison L, et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Supportive Care in Cancer 2004;12:268-73.
30. Simmonds MA. Oral transmucosal fentanyl citrate produces pain relief faster than medication typically used for breakthrough pain in cancer patients. Proceedings of the American Society of Clinical Oncology 1997;16:52a.
31. Stanley K. Gever L. Wheeler W. Evaluation of fentanyl buccal soluble film (FBSF) in opioid tolerant cancer patients with neuropathic breakthrough cancer pain (BTP). Journal of Pain 2011;12(4 Suppl):P50.
32. Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R. Fentanyl Pectin Nasal Spray 043 Study Group. Fentanyl pectin nasal spray in breakthrough cancer pain. Journal of Supportive Oncology 2010;8(4):184-90.
33. Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. Pharmacy and Therapeutics 2005;30:354-61.
34. Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. European Journal of Pharmaceutical Sciences 2003;20(3):327-34.
35. Bruera E, Scholler T, Wenk R, MacEachern T, Marcellino S, Hanson J, et al. A prospective multi-center assessment of the Edmonton staging system for cancer pain. Journal of Pain Symptom Management 1995;10:348-55.
36. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. Pain 1999;82:263-74.
37. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology 2012;13(2):58-68.
38. Colleau SM. The significance of breakthrough pain in cancer. Cancer Pain Release 1999;12(4):1-3.
39. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. Journal of Clinical Pharmacology 2007;47(3):343-50.
40. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain 2009;13(4):331-8.
41. Diaz del Consuelo I, Falson F, Guy RH, Jacques Y. Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl. Journal of Controlled Release 2007;122(2):135-40.
42. Elsner F, Zeppetella G, Porta-Sales J, Tagarro I. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Clinical Drug Investigation 2011;31(9):605-18.
43. Farrar JT, Portenoy RK, Berlin JA, Klinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94.
44. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. Journal of Pain and Symptom Management 2003;25(5):406-11.
45. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalisations, emergency department visits, and physicians office visits reported by cancer patients with and without history of breakthrough pain. Journal of Pain 2002;3:38-44.
46. Fortner BV, Demarco G, Irving G, Ashley J, Keppler G, Chavez J, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. Journal of Pain and Symptom Management 2003;25(1):9-18.
47. Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer 2001;84:587-93.
48. Hanks G. Oral transmucosal fentanyl citrate for the management of breakthrough pain. European Journal of Palliative Care 2001;8(1):6-9.
49. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
50. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical centre. Pain 2003;101:55-64.
51. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports on randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
52. McQuay HJ, Barden J, Moore RA. Clinically important changes -what's important and whose change is it anyway?. Journal of Pain and Symptom Management 2003;25(5):395-6.
53. Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. Journal of Pain and Symptom Management 2004;27(4):353-9.
54. National Institute for Health and Clinical Excellence. Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults. NICE clinical guideline 140, 2012. guidance.nice.org.uk/CG140 (accessed 10 September 2013).
55. Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncology (Willison Park NY) 1989;3(8 Suppl):25-9.
56. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34.
57. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
58. Savarese JJ, Thomas GB, Homesley H, Hill CS. Rescue factor: a design for evaluating long-acting analgesics. Clinical Pharmacology and Therapeutics 1988;43:376-80.
59. Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer pain. A national clinical guideline, 2008. www.sign.ac.uk/guidelines/fulltext/106/index.html (accessed 10 September 2013).
60. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opinion on Drug Delivery 2009;6(5):543-52.
61. Zeppetella G, Ribeiro MDC. The pharmacotherapy of cancer-related episodic pain. Expert Opinion in Pharmacotherapy 2003;4(4):493-502.
62. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. Journal of Pain and Symptom Management 2008;35:563-7.
63. Zeppetella G. Breakthrough pain in cancer patients. Clinical Oncology 2011;23(6):393-8.
64. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004311.pub2]